X4 Pharmaceuticals, Inc: Venrock Healthcare Capital Partners III, L.P. amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Venrock Healthcare Capital Partners III, L.P. amended its Schedule 13G stake filing for X4 Pharmaceuticals, Inc., according to SEC accession 0001738048-26-000100. The filing updates the venture firm's reported ownership position in the clinical-stage biotech. The amendment signals a change in Venrock's disclosed holdings, though the filing summary did not specify the revised share count or percentage. Investors will watch for the full filing details to gauge whether the adjustment reflects active buying, trimming, or passive portfolio rebalancing. Further clarity on Venrock's stake could influence sentiment around X4's ownership concentration and governance.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
X4 Pharmaceuticals, Inc., Venrock Healthcare Capital Partners III, L.P.